FDA Approval: New Drugs & Medical Devices

FDA Approval: New Drugs & Medical Devices

공개
NeoDrop Official
NeoDrop Official

Weekly FDA approvals of new drugs (NDA / BLA) and medical devices (510(k), PMA), with target indication and commercial impact

FDA Approval: New Drugs & Medical Devices
FDA Approval: New Drugs & Medical Devices

FDA clears Penumbra Thunderbolt CAVT — stroke clearance, June 11 2026

Following Thursday's five-item roundup, this brief mid-week update covers the single FDA 510(k) clearance issued Friday: Penumbra's Thunderbolt, the first computer-assisted vacuum thrombectomy (CAVT) system with modulated aspiration cleared for acute ischemic stroke. The focused analysis covers device mechanism, the 3-year THUNDER IDE trial journey (including the August 2023 FDA-mandated safety endpoint change), competitive context against stent retriever platforms in an ~$830–890M market, and investor signals around the pending $14.5B Boston Scientific acquisition.

FDA Approval: New Drugs & Medical Devices
FDA Approval: New Drugs & Medical Devices

Five FDA actions in five days: approvals, June 6–11, 2026

Five FDA actions closed the June 6–11 window: Eli Lilly's Ebglyss gained an every-8-week maintenance option for atopic dermatitis — cutting annual injections from 13 to 6; Pfizer's Hympavzi expanded to hemophilia A/B patients ages 6–11 and older patients with inhibitors, becoming the first subcutaneous non-factor therapy for pediatric hemophilia B; Medtronic's Nellcor with Nell-EQ achieved FDA 510(k) clearance with SpO₂ accuracy of 1.33%–1.69% RMS across light, medium, and dark skin tones; and KARL STORZ's Rubina Lens brought NIR/ICG fluorescence imaging to open surgery.

FDA Approval: New Drugs & Medical Devices
FDA Approval: New Drugs & Medical Devices

Triformis leads a quiet week: FDA approvals, May 29–June 5, 2026

Edwards Lifesciences' Triformis Resilia — the first surgical valve purpose-built for the tricuspid position — anchors a week that also delivered a China-originated IV anesthetic (Cypsedo), a reformulated CML drug solving a key drug-interaction constraint (Cavhanza), and six device clearances spanning AI radiation planning, faster blood culture, handheld OR navigation, automated cardiac AI, and two imaging/fixation platforms.

전체 콘텐츠 아카이브 보기더 많은 채널 찾기